BlossomHill Therapeutics, Inc. filed a Form 8-K with the SEC on September 15, 2026, disclosing updated clinical data from its ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer patients, presented at the IASLC 2026 World Conference on Lung Cancer.

Key Highlights

  • Trial update disclosed: BlossomHill Therapeutics announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer (NSCLC) patients.
  • Target patient population: The trial focuses on NSCLC patients with secondary epidermal growth factor receptor (EGFR) resistance mutations, such as EGFR C797S, according to the filing.
  • Conference presentation: The data were highlighted in a mini-oral presentation at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea.
  • Filing classification: The disclosure was made under Item 7.01 (Regulation FD) and is furnished, not filed, meaning it is not subject to Section 18 liabilities of the Securities Exchange Act of 1934.
  • Signed by CEO: The report was signed by J. Jean Cui, Ph.D., President and Chief Executive Officer of BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Shares SOLARA Trial Update at IASLC 2026

According to the filing, BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) issued a press release on September 15, 2026, announcing updated data from its Phase 1/2 SOLARA trial. The trial is evaluating BH-30643 in NSCLC patients who have developed secondary EGFR resistance mutations, specifically citing EGFR C797S as an example. The data were presented in a mini-oral session at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer, held in Seoul, South Korea.

The company disclosed the information under Item 7.01 of Form 8-K, which covers Regulation FD disclosures. The filing states that the information in Item 7.01 and the attached press release (Exhibit 99.1) "shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section." The filing also notes the information shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933.

BlossomHill Therapeutics is incorporated in Delaware and is headquartered at 10255 Science Center Drive, Suite 200, San Diego, California 92121. The company is identified in the filing as an emerging growth company. The full text of the press release, which contains the detailed clinical data, was furnished as Exhibit 99.1 to the Current Report but was not reproduced within the body of the 8-K itself.

What Was Disclosed

BlossomHill Therapeutics filed an 8-K on September 15, 2026, reporting updated Phase 1/2 SOLARA trial data for BH-30643 in EGFR-resistant NSCLC patients, presented at the IASLC 2026 World Conference on Lung Cancer in Seoul. The press release with full data details was furnished as Exhibit 99.1.